Dr. Schlam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Washington St
Boston, MA 02111Phone+1 617-636-6227Fax+1 617-636-8538
Summary
- Dr. Ilana Schlam is a breast medical oncologist in Boston, MA and is affiliated with Tufts Medical Center. She received her medical degree from Universidad Anahuac School of Medicine in Mexico City, internal medicine training at The Jewish Hospital of Cincinnati and completed her fellowship training at Georgetown-Washington university Hospitals in Washington, DC.
Education & Training
MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 2018
MedStar Washington Hospital CenterOncology, 2021- MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 2021
Jewish Hospital of CincinnatiChief Residency, Internal Medicine, 2017 - 2018- Jewish Hospital of CincinnatiResidency, Internal Medicine, 2015 - 2018
Universidad Anahuac School of MedicineClass of 2014
Certifications & Licensure
MA State Medical License 2021 - 2025
DC State Medical License 2018 - 2022
OH State Medical License 2015 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Research Scholar Award, Jewish Hospital—Mercy Health 2018
- Young Achiever, American College of Physicians 2018
- Recognized for Academic Excellence, Anahuac University 2008-2011
Publications & Presentations
PubMed
- The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer.Ilana Schlam, Sara M Tolaney, Paolo Tarantino
Expert Review of Anticancer Therapy. 2024-11-01 - Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study.Ilana Schlam, D Max Smith, Cody Peer, Tristan Sissung, Keith T Schmidt
NPJ Breast Cancer. 2024-09-30 - Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients with Metastatic Breast Cancer: The LEANORA study.Sandra Swain, Ilana Schlam, D Max Smith, Cody Peer, Tristan Sissung
Research Square. 2024-08-13
Journal Articles
- PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma.(3) Panchabhai S, Schlam I, Sebastian S, Fonseca R., Leukemia, 1/1/2017
- Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.(7) Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba D, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Ste..., Blood Cancer Journal, 2016
- Bevacizumab in the Treatment of Brain Metastases, Is There Still a Role? An Updated Review of the Literature.(1) Schlam I, Aragon-Ching JB, Veytsman I, Current Analysis in Oncology, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
